



Laboratory Director: Dr. Manoj Tyagi, PhD. NRCC - CC, FAAC/FACB

PLEASE ATTACH: COPY OF INSURANCE CARD (FRONT/BACK) AND DEMOGRAPHIC SHEET
 Missing Information May Delay Turn-Around-Time and Reporting of Results.

1 PATIENT INFORMATION **Collection Date:**

| | | | |
|-------------------------------|----------------------------------|-----------|-------|
| Facility name (if applicable) | Attach Facesheet of patient info | | |
| Patient Name (Last) | (First) | (Middle) | |
| Date of Birth | Race | Ethnicity | |
| Social Security Number | Gender | | |
| Address | | | |
| City | State | Zip | Phone |

3 INSURANCE INFORMATION Clearly mark all mandatory billing sections

Is this patient a **SKILLED (Medicare A) patient?** YES NO

| | | |
|-----------------------|-------------|----------------|
| Primary Insurance | Policy # | Group# |
| Person Insured | Self/Spouse | DOB of Insured |
| Secondary Insurance | Policy # | Group# |
| Person Insured | Self/Spouse | DOB of Insured |
| Prior Authorization # | | |

2 PROVIDER INFORMATION

| | | |
|----------------|-------|-------|
| Practice Name | | |
| Address | | |
| City | State | Zip |
| Phone | Zip | Fax |
| Physician Name | | NPI # |

Are you a mobile provider YES NO If yes, fill out section #1 in its entirety.
 Does patient live in Residential Home LTC

4 BILLING INFORMATION

Please bill my credit card: AMEX MasterCard Visa Discover

Name as it appears on card:

Account #:

Expiration Date: CVC:

Amount: Date:

I have been notified of the test cost and understand that my credit card will be charged the full amount for the testing. Patient Signature Section, please add "Patient signature is required for patients with TRICARE insurance.

Patient/Guardian Signature:

TEST SELECTION CHECK APPLICABLE BOXES **Sample Type / Location:**

ALLERGIES: **Renal FXN:** NML ABNL **Hepatic FXN:** NML ABNL

MARKERS: Pregnant Warfarin Recurrent UTIs Immunocompromised Renal compromised Dialysis Hepatic compromised Catheter

UTI PANEL - ORGANISM TESTED WITH ABR
 Check this box for testing entire panel

| | |
|--|--|
| BACTERIUM | FUNGAL |
| <input type="checkbox"/> Acinetobacter baumannii | <input type="checkbox"/> Candida albicans |
| <input type="checkbox"/> Chlamydia trachomatis | <input type="checkbox"/> Candida auris |
| <input type="checkbox"/> Citrobacter freundii | <input type="checkbox"/> Candida glabrata |
| <input type="checkbox"/> Enterobacter aerogenes | <input type="checkbox"/> Candida parasilopsis |
| <input type="checkbox"/> Enterobacter cloacae | <input type="checkbox"/> Candida tropicalis |
| <input type="checkbox"/> Enterococcus faecalis | PARASITIC |
| <input type="checkbox"/> Enterococcus faecium | <input type="checkbox"/> Trichomonas vaginalis |
| <input type="checkbox"/> Escherichia coli | |
| <input type="checkbox"/> Klebsiella oxytoca | |
| <input type="checkbox"/> Klebsiella pneumoniae | |
| <input type="checkbox"/> Morganella morganii | |
| <input type="checkbox"/> Mycoplasma genitalium | |
| <input type="checkbox"/> Mycoplasma hominus | |
| <input type="checkbox"/> Neisseria gonorrhoeae | |
| <input type="checkbox"/> Proteus mirabilis | |
| <input type="checkbox"/> Proteus vulgaris | |
| <input type="checkbox"/> Providencia stuartii | |
| <input type="checkbox"/> Pseudomonas aeruginosa | |
| <input type="checkbox"/> Serratia marcescens | |
| <input type="checkbox"/> Staphylococcus aureus | |
| <input type="checkbox"/> Staphylococcus saprophyticus | |
| <input type="checkbox"/> Streptococcus agalactiae | |
| <input type="checkbox"/> Streptococcus pyogenes | |
| <input type="checkbox"/> Treponema pallidum (syphilis) | |
| <input type="checkbox"/> ureaplasma parvum | |
| <input type="checkbox"/> Ureaplasma urealyticum | |

ANTIBIOTIC RESISTANCE GENES
 These are automatically tested in Reflex ABX - only when positives are detected.

Aminoglycoside Resistance
 AmpC beta lactamase ACT/MIR, FOX, ACC Groups
 Class A beta lactamase CTX-M1 (15), M2 (2), M9 (9), M8/25
 Class A beta lactamase SHV, KPC Groups
 Class B metallo beta lactamase IMP, NDM, VIM Groups
 Class D oxacillinase OXA-48, -51
 Extended Spectrum Betalactamases Resistance Gene TEM G236S
 Fluroquinolone Resistance Genes qnrA1, qnrA2, qnrB(qnrS)
 Macrolide Lincosamide Streptogramin Resistance ermB, ermC, ermA
 Methicillin Resistance Gene mecA
 Tetracycline Resistance Gens tetB, tetM
 Trimethoprim/Sulfamethoxazole Resistance dfr(A1,A5), sul(1,2)
 Vancomycin Resistance Genes VanA, VanB

PHARM D GUIDANCE
 PhD Pharmacist driven interpretation of your patient's specific infection and antibiotic resistance markers for effective antibiotic recommendations consistent with Antibiotic Stewardship.

MEDICAL NECESSITY MUST BE COMPLETED
 ICDs Listed for Convenience Only - Please document applicable ICD-10 Codes.

| | |
|--|---|
| <input type="checkbox"/> N30.0 Acute cystitis | <input type="checkbox"/> R50.9 Fever, unspecified |
| <input type="checkbox"/> N30.1 Interstitial cystitis (chronic) | <input type="checkbox"/> R53.82 Chronic fatigue, unspecified |
| <input type="checkbox"/> N39.0, UTI, site not specified | <input type="checkbox"/> R68.83 Chills (without fever) |
| <input type="checkbox"/> N40.1 BPH w/lower UTI symptoms | <input type="checkbox"/> Z11.3 Encounter for screening for infections with a predominantly sexual infections with a predominantly sexual mode of transmission |
| <input type="checkbox"/> N97.0-N97.9 Female infertility | <input type="checkbox"/> Z11.51 Encounter for screening of human papillomavirus (HPV) |
| <input type="checkbox"/> R21 Rash and other nonsp skin eruption | <input type="checkbox"/> Z20.2 Exposure to disease that is predominantly sexually transmitted |
| <input type="checkbox"/> R30.0 Dysuria | <input type="checkbox"/> Z79.899 Other long-term (current) drug therapy |
| <input type="checkbox"/> R30.9 Painful micturition, unspecified | <input type="checkbox"/> _____ |
| <input type="checkbox"/> R31.0 Gross hematuria | <input type="checkbox"/> _____ |
| <input type="checkbox"/> R31.29 Other microscopic hematuria | <input type="checkbox"/> _____ |
| <input type="checkbox"/> R35.0 Frequency of micturition | |
| <input type="checkbox"/> R39.15 Urgency of urination | |
| <input type="checkbox"/> R39.9 Unspec. symptoms and signs involving the genitourinary system | |

Patient Consent
 I am voluntarily seeking laboratory service and hereby consent to provide a sample as requested. I have the right to refuse testing, but I understand this may impact my treatment. This agreement can be revoked by me at any time with written notification and is valid until revoked. I hereby assign to the laboratory my right to insurance benefits that may be payable to me for services provided arising from any insurance policy, self-insured health plan, Medicare or Medicaid in my name or on my behalf. I further authorize payment of benefits directly to the laboratory. I understand acceptance of insurance does not relieve me from any responsibility concerning payment for laboratory services and that I am financially responsible for all charges whether or not they are covered by my insurance. I understand that any payment I receive for services rendered by the laboratory from my insurance provider should be forwarded to the laboratory immediately.

Patient Signature: _____ **Date:** _____

Medical Provider Consent
 This test is medically necessary for the risk assessment, diagnosis or detection of a disease, illness, impairment, symptom, syndrome or disorder. The results will determine my patient's medical management and treatment decisions. By my signature below, I indicate that I am the referring physician or authorized health care provider. I have explained the purpose of the test. The patient has been given the opportunity to ask questions and/or seek further counsel. The patient has voluntarily decided to have the test performed by Vero Diagnostic Lab. As the medical provider, I am responsible for documenting applicable ICD-10 diagnosis codes.

Medical Provider Signature: _____ **Date:** _____

00000000

Patient Name: _____

Patient D.O.B. _____